Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows:
Date: Monday, January 10, 2022
On Demand Time: 7:00AM ET
Webcast: https://journey.ct.events/view/b39a70c0-7058-4a1f-ba97-e18b13918fc7
   

The presentation will be webcast on-demand and available for 30 days thereafter using the link provided above and via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica Pharmaceuticals plcOsmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ®.

Osmotica has operations in the United States and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plcLisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com

Grafico Azioni Osmotica Pharmaceuticals (NASDAQ:OSMT)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Osmotica Pharmaceuticals
Grafico Azioni Osmotica Pharmaceuticals (NASDAQ:OSMT)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Osmotica Pharmaceuticals